FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma

NCT07221032 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Relapse Multiple Myeloma
Refractory Multiple Myeloma

Interventions

BIOLOGICAL: FT836 CAR T cells (1 x 10^8 cells per dose)
BIOLOGICAL: FT836 CAR T cells (3 x 108 cells per dose)
BIOLOGICAL: FT836 CAR T cells (up to 9 x 108 cells per dose)
DRUG: Daratumumab 16 mg/kg

Sponsor

Medical College of Wisconsin